40 results about "Infusion reaction" patented technology

The invention discloses an automatically regulating infusion method and a device thereof. The method comprises the following steps: firstly, a preset infusion mode is selected through a user interface of a control unit, the control unit outputs control signals to a medical pump, and the medical pump works according to infusion parameters with an assured preset infusion mode to carry out infusion on a patient; secondly, an inductor collects physiological parameters of the patient and outputs physiological parameter signals to the control unit; thirdly, the control unit receives the physiological parameter signals, outputs the control signals to the medical pump after calculation, and regulates infusion parameters of the medical pump. The automatically regulating infusion device comprises the control unit, the medical pump and the inductor used for collecting the physiological parameters of the patient. The invention detects infusion reaction of the patient in real time in an infusion process, and regulates the infusion parameters through feedback of the physiological parameters of a human body, thereby the infusion process is matched with the individual characteristics, the effects of infusion and drug input are enhanced, and complications of the infusion and the drug input are reduced or avoided.

The invention relates to the technical field of transfusion monitoring, and discloses a physician, nursing and pharmacy integrated omnibearing reasonable safety transfusion early-warning monitoring method. The method comprises the following flow: receiving a transfusion prescription and doctor advice information from a doctor work station, extracting pharmacy information, examination information and vital sign information from the prescription and doctor advice information; selecting a transfusion pharmacy knowledge base from a reasonable safety transfusion knowledge base rule base, wherein the reasonable transfusion pharmacy knowledge base comprises pharmacy rule information, clinic rule information, a medicine and pharmacy literature database and public prescription evaluation rule information. The method provided by the invention achieves the automatic screening and evaluation of the infusion reaction risks through the biochemical indexes of a patient, achieves the safety checking of a tool, achieves the marking and prompt of dripping speed, light avoiding and transfusion stable time, helps a nurse carry out the medication safety monitoring and take measures, and guarantees themedication safety.

The invention relates to a medicine bottle operation needle and a processing method thereof, which relate to the field of medical apparatuses. The medicine bottle operation needle comprises a syringe needle and a needle tube, wherein the syringe needle is provided with a second bevel close to a needle point, a first bevel on the rear of the second bevel, and an inner bevel inclined inwards within 50 to 70 percent of an area of the whole edge of an opening of the first bevel and the edge of an opening of the second bevel which is connected with the first bevel; and the operation needle can be an infusion bottle dropping funnel needle, an infusion bottle air inlet needle or a dispensing diluting needle. The processing method for the operation needle is to grind two-thirds of the wall thickness of the needle tube again to form the inner bevel on the basis of grinding to form the first bevel and the second bevel. The operation needle processed by the method has a novel structure, is smooth to insert, can completely stop pollution of rubber stopper particles under the condition of medicine supply through stems, reduces infusion reaction, improves the use efficiency and the safety of the operation needle, and is a novel generation of product of the medicine bottle operation needle.

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

The invention discloses a medical manual automatic control secondary filter valve belonging to the technical field of medical appliances. The medical manual automatic control secondary filter valve comprises a valve body, a fixing ring, a valve core, a spring, a regulating screw, a bolt, a rubber gasket, a rubber cushion, a filter film and a valve nozzle. The pressure difference of the valve is regulated by rotating the regulating screw, a secondary filter film filters media, and the outlet end of the valve is an outer cone joint of 6:100. When the medical manual automatic control secondary filter valve is used, the pressure difference of the valve can be arbitrarily regulated; when the pressure difference of both ends of the valve exceeds a predetermined value, the valve core is automatically opened; and when the valve core is deadlocked or needed, the valve core can be manually opened by pressing a cylinder arranged at the upper end of the valve core. When air pressure exists, a connection injection needle can distinguish and inflate vacuum medicines to prevent the medicines and a whole transfusion system from being polluted by bacteria, viruses, and dust particulates and prevent infusion reaction.

The invention discloses externally applied traditional Chinese medicine powder for treating cold, which is characterized in that the externally applied traditional Chinese medicine powder comprises the following traditional Chinese medicine components by weight: 19 to 23% parts of evodia rutaecarpa, 15 to 19% of cinnamon, 9 to 12% of sinapsis alba, 17 to 21% of asarum herb, 10 to 15% of euphorbia kansui, 11 to 15% of rhizoma typhoon, and 7 to 17% of flour. According to the invention, all traditional Chinese medicine components are crushed into fine powder, and then the powder is mixed with the flour to obtain traditional Chinese medicine powder for treating cold. The traditional Chinese medicine powder for treating cold is for external use based on acupuncture points. Compared with present medicine for treating symptoms including acute fever, cough, snivel, sore throat, and headache caused by cold, the externally applied traditional Chinese medicine powder for treating cold provided in the invention has good treatment effects, can be used conveniently, and brings little suffering to the patient. Besides, the medical expenses are low; the occurrence of toxic side effects and infusion reaction can be avoided. Therefore, the externally applied traditional Chinese medicine powder for treating cold provided in the invention is especially suitable for low-income patients or patients not suitable for injection treatment.

The invention provides a medical panel type precision flow regulator. The medical panel type precision flow regulator comprises a base and a rotary handle mounted on the base. The size of the inside of a flow channel is adjusted by rotating the rotary handle to adjust the fluid flow. The medical dial type precision flow regulator can be used in an ICU (intensive care unit), an operating room, an emergency room, an anesthesia section and a variety of places requiring precise infusion for meeting the precision requirements for the liquid infusion. The medical panel type precision flow regulator can be used for infusion of some specific medicine, especially for some irritant medicine prone to infusion reaction, such as azithromycin. The medical panel type precision flow regulator is controlled through a knob for intuitively and easily regulating the flow and is provided with a panel scale for easily confirming the infusion flow.

The invention relates to the field of medicinal chemistry and particularly relates to a full humanized HER2 antibody as well as a coding gene and an application thereof. According to the full humanized HER2 antibody, the amino acid sequence of the heavy chain variable region is SEQ ID NO:1 and the amino acid sequence of the light chain variable region is SEQ ID NO:2. By adopting the full humanized HER2 antibody, the infusion reaction and the immunogenicity can be reduced, the safety of the medicine can be increased and the better pharmacodynamic characteristics can be obtained.

The invention relates to the technical field of medicinal preparations, in particular to a mannitol injection. The mannitol injection is prepared from the following raw materials in percentage by weight: 12 to 19 percent of mannitol, 0.5 to 1.3 percent of a jasmine extract, 0.8 to 1.6 percent of a pseudo-ginseng extract, and the balance of injection water, and the total percent is 100. Compared with the prior art, the mannitol injection provided by the invention has a good treatment effect and a good effect on treating high intracranial pressure caused by cerebral hemorrhage, does not crystallize at a low temperature, and is high in use safety and convenient to use clinically; hypersensitivity is avoided; adverse reactions, such as an infusion reaction, are remarkably reduced.

The invention discloses a heating thermal-insulation sleeve which relates to the technical field of heating equipment and comprises an annular sleeve equipped with a transparent observation window, wherein the annular sleeve is composed of an inner ring thermal-insulation layer as well as a heating layer and an outer thermal-insulation layer which are successively overlaid outside the inner ring thermal-insulation layer; the heating layer is a bag body filled with an electrically conductive liquid, and a temperature sensor is disposed in the bag body; and a temperature display and a buzzing alarm electrically connected to the temperature sensor are disposed on the outer thermal-insulation layer. In comparison with the prior art, the heating thermal-insulation sleeve disclosed by the invention can solve the problem of infusion reactions which are generated from a patient due to low-temperature infusion.

The invention relates to the technical field of pharmaceutic preparations, in particular to compound mannitol injection. The compound mannitol injection is prepared from, by weight, 6-10% of mannitol, 3-9% of sorbitol, 1-6% of Tween 80, 1-5% of olive oil, 0.4-0.6% of sodium chloride and the balance injection water. The compound mannitol injection is good in treatment effect, does not crystallize at low temperatures, is high in using safety performance, can not cause allergies, can be used conveniently clinically, and is capable of reducing adverse reactions including infusion reactions remarkably.

The invention relates to the technical field of pharmaceutical preparations, in particular to a compound mannitol injection, which is made of the following raw materials in percentage by weight: mannitol 6-10%, sorbitol 3-9%, Tween 80 1-6%, olive Add 1-5% oil, 0.4-0.6% sodium chloride, and water for injection to 100%. The compound mannitol injection of the invention has good curative effect, no crystallization at low temperature, high use safety, no allergy phenomenon, convenient clinical use, and significantly reduces adverse reactions such as infusion reactions.

The present disclosure relates to a method of treating at least one Cell-Associated Neurotoxicity Syndrome (ICANS), cancer-related cognitive impairment, Infusion Reaction Syndrome (IRS), Capillary Leak Syndrome (CLS), Tumor Lysis Syndrome (TLS), Macrophage Activation Syndrome (MAS), Systemic Inflammatory Response Syndrome (SIRS), Immune Reconstitution Inflammatory Syndrome (IRIS), Graft-Versus-Host Disease (GVHD), Acute Respiratory Distress Syndrome (ARDS), sepsis, Ebola, avian influenza, smallpox, Systemic Inflammatory Response Syndrome (SIRS), and Immune-related Adverse Events Syndrome (IrAES) in a subject in need thereof, comprising administering a mast cell stabilizer or a compound of Formula I or Formula II: Formula I, Formula II, wherein R1 is halogen, OH, or —OC(O)C1-5alkyl R2 and R3 are each independently selected from CO2R4 or CH2OR5; R4 is i L, Na, K, H, C1-5alkyl, or —CH2CO(C1-5alkyl); and R5 is H or C(O)(C1-5alkyl), or a pharmaceutically acceptable salt thereof.

The invention relates to the field of medicinal chemistry and specifically relates to a fully humanized HER2 antibody as well as an encoding gene and an application of the antibody. The amino acid sequence of the heavy chain variable region of the fully humanized HER2 antibody is as shown in SEQ ID NO: 1, while the amino acid sequence of the light chain variable region of the fully humanized HER2 antibody is as shown in SEQ ID NO: 2. The fully humanized HER2 antibody is capable of reducing infusion reaction immunogenicity and improving the drug safety, and has better pharmacokinetic characteristics.

The invention discloses a disposable locking type pressure precise filtering closed infusion set belonging to the technical field of medical appliances. The invention adopts the technical scheme as follows: the disposable locking type pressure precise filtering closed infusion set consists of a disposable locking type precise filtering infusion set and an air-storing bag, wherein the disposable locking type precise filtering infusion set comprises a bottle plug puncture unit projecting jacket, a bottle plug puncture unit, a burette, an injection piece, a dropping funnel, a liquid medicine precise filter, a pipeline, a flow rate adjustor, an outer conical joint, an outer conical joint protecting jacket, a locking type outer conical joint and a floating ball; and the air-storing bag comprises a bag body, a pipeline, a flow rate adjustor, a locking type inner conical joint, an inner conical joint protecting plug and an air precise filter. The disposable locking type pressure precise filtering closed infusion set can realize the locking type connection of the air-storing bag and the disposable locking type precise filtering infusion set and adopts high-pressure clean air in the air-storing bag as the power for infusing the liquid medicine, in addition, the liquid medicine is precisely filtered, and fully closed infusion can be performed quickly with controllable flow rate of the liquid medicine. The invention can avoid air pollution in the infusion process, can prevent bacteria, virus and dust from entering the human body, prevent infusion reaction and phlebitis from occurring and prevent air embolism from generating caused by negligence of personnel to endanger the life.

The invention discloses a polymer PTC constant temperature heating transfusion device, which comprises a transfusion tube; along the transfusion tube, a bottle inserting needle, a drip tube, a flow regulator and a constant temperature heating jacket are arranged sequentially from top to bottom; the constant temperature heating jacket includes Insulation layer, heating layer and heat transfer layer, the insulation layer, heating layer and heat transfer layer are wrapped on the outer skin of the infusion tube sequentially from the outside to the inside; the infusion tube is provided with at least one pulling device. Beneficial effects of the present invention: Since the infusion tube is provided with a constant temperature heating jacket, the medicinal liquid or blood preparation device passing through the infusion tube is firstly heated and then enters the patient's body. The air bubbles are eliminated to ensure that the infused liquid is close to body temperature and eliminate the adverse reactions of infusion caused by air bubbles.

The invention relates to the field of medicinal chemistry, in particular to two fully human HER2 antibodies, their coding genes and applications. The present invention provides two fully human HER2 antibodies, wherein the amino acid sequence of the heavy chain variable region of one HER2 antibody is SEQ ID NO: 1, the amino acid sequence of the light chain variable region is SEQ ID NO: 2, and the other The amino acid sequence of the heavy chain variable region of the HER2 antibody is SEQ ID NO:10, and the amino acid sequence of the light chain variable region is SEQ ID NO:11. The fully human HER2 antibody can reduce infusion reactions and immunogenicity, improve drug safety, and have better pharmacokinetic characteristics. In addition, the fully human antibody of the present invention can be used in combination with other HER2-positive tumor therapeutic agents to treat HER2-positive tumors.

Certain embodiments of the invention provide methods of ameliorating an infusion reaction in a mammal in need thereof.

The invention discloses an infusion robot. The robot comprises a robot main body, a display screen, a scanning device, a replacer, a disinfection box, an induction clamp and a fixing clamp, wherein the scanning device is arranged on a left arm of the robot main body; the replacer, the disinfection box and the fixing clamp are arranged on a right arm of the robot main body; the display screen is arranged on the abdomen of the robot main body; and the induction clamp is in signal connection with the robot main body through a wireless network. According to the infusion robot, the workload of nursing personnel can be effectively reduced, so that the nursing personnel have more time to truly serve patients; physical and chemical injuries to medical personnel can be effectively reduced in the process of replacing an infusion bottle; various infusion reactions can be prevented in the infusion bottle replacing process, so that the risks of cross infection and sterile infusion pollution are reduced; and medical potential safety hazards existing in the infusion process can be effectively reduced, so that the accuracy of infusion bottle replacement is improved.

The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of an angiosarcoma in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol or paclitaxel formulated with Cremophor) therapy in a subject suffering from an angiosarcoma.

The present disclosure provides pharmaceutical combinations of orally administered docetaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered docetaxel (e.g., Taxotere® or docetaxel formulated with polysorbate 80) therapy in a subject suffering from cancer.

The invention discloses a postoperative patient supervision system for neural interventional therapy, relates to the technical field of postoperative patient supervision, and is used for solving the problems that in existing postoperative patient supervision for neural interventional therapy, body characteristic data of a patient cannot be supervised and analyzed, the infusion speed of the patient cannot be adjusted, and infusion reaction is likely to occur. The system comprises a supervision module and an adjustment module, and the supervision module sends the body characteristic data to a server and analyzes the body characteristic data to obtain an adjustment signaling; after receiving the adjusting signaling, the adjustment module analyzes the adjusting signaling to obtain an adjusting interval, and the adjustment module is triggered through the adjusting interval to adjust the infusion rate of the patient; the supervision module carries out data supervision and analysis on a postoperative patient subjected to neural interventional therapy to obtain the adjustment interval; and the infusion speed of the postoperative patient subjected to neurointervention treatment is reasonably adjusted by the adjustment interval. The problems of blood pressure reduction, body temperature rise and the like caused by too fast infusion are avoided.

The invention discloses a manufacturing method of an infusion indwelling part connector for reducing hospital infection.The manufacturing method is characterized by including the following steps that firstly, a steel needle is manufactured or purchased, wherein a conical needle tip is produced or purchased, the steel needle located on the rear side wall of the rear edge of the conical needle tip is holed, and the diameter of the steel needle ranges from 0.3 mm to 0.9 mm; secondly, the steel needle and a needle base are bonded or riveted or welded; thirdly, or, the steel needle and other parts are further bonded or heat-sealed or welded or assembled, packaged, sterilized and checked out, and then the infusion indwelling part connector is obtained.According to the manufacturing method of the infusion indwelling part connector, the structure is simple and reasonable, the probability of occurrence of hospital infection, infusion reaction and allergy caused when attachments on the infusion end face of an infusion indwelling part enter the blood vessel of the human body can be reduced, connecting and fixing are convenient, and thus the use safety of an existing infusion instrument can be improved.

A multifunctional anti-drop infusion device comprises an infusion needle socket (6) and is characterized in that one side of the infusion needle socket (6) is provided with a tooth clamp (5), the tooth clamp (5) comprises a jacket (50), one end of the jacket (50) is provided with a shifting block (51), the inner side of one end of the jacket (50) and the outer side of the other end of the jacket (50) are respectively provided with a plurality of inverted teeth (52). One side of a puncture needle of an infusion bag is provided with an air inlet pipe, and the top end of the air inlet pipe is connected with a filtering and ventilating membrane which can prevent liquid medicine from being discharged and enable air to enter, and has a filtering effect on the air; according to the invention, thetooth clamp can be connected with the infusion bag (or an infusion bottle) into a whole, so that the infusion device is effectively prevented from being pulled and dropping to cause the waste of liquid medicine or the infusion reaction caused by back insertion.